Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for ...

Arbutus continues to consult closely with and support its exclusive licensee, Genevant Sciences, to protect and defend Arbutus’s intellectual property, which is the subject of on-going lawsuits ...

Arbutus Biopharma is dumping one of its Roivant-backed programs after two healthy people in a phase 1 study developed acute hepatitis—the very disease the drug was supposed to treat. The company was ...

Roivant Sciences and Moderna Therapeutics, two of the most highly-funded and controversial companies in the biotechnology world, are headed for a collision course over medical technology. On Monday, ...

April 11 (Reuters) - A U.S. appeals court handed Moderna Inc (MRNA.O), opens new tab a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp (ABUS.O), opens new tab patent related ...

TALKED WITH AN EYEWITNESS. THE WITNESS MAY BE KEY TO THIS INVESTIGATION BECAUSE THERE IS NO POLICE BODY CAM FOOTAGE. A WITNESS TO THE POLICE DEADLY SHOOTING CALLS IT JUSTIFIED. HE SPOKE WITH THE 11 ...

Arbutus Biopharma (NASDAQ:ABUS) quickly soared 19% after a claim construction order in a Covid vaccine patent dispute with Moderna (NASDAQ:MRNA) according to a court filing on Wednesday. Moderna fell ...

It’s a David-and-Goliath fight between two unprofitable startups. Moderna Therapeutics is valued by its private investors at $5 billion, as it promises to create a new kind of medicine that will turn ...